MedTrace Logo

Clinical, Biological and NMR Outcome Measures Study for Hereditary Inclusion Body Myopathy Due to Mutation of UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine Kinase Gene (GNE)

NCT02196909 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2018-08-08

No results posted yet for this study

Summary

The objective of the study is to identify the best clinical and biological outcome measures for further therapeutics approaches.

Conditions

  • HIBM

Interventions

OTHER

motor function and strength assessment

OTHER

NMR assessment

OTHER

24h urine and serum collection

Sponsors & Collaborators

  • Institut de Myologie, France

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-07-31
Primary Completion
2018-05-31
Completion
2018-05-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02196909 on ClinicalTrials.gov